IGF1R and urinary bladder cancer: Finally, by analyzing the GDSC database, we found that ATM mutations resulted in increased bladder cancer sensitivity to 29 drugs, including cisplatin, the first-line treatment for bladder cancer, and BMS-536924, an IGF-1R inhibitor.